clinical trial · NCT04940039
A Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings
Janssen-Cilag International NV·phase4·completed·n = 93
SchizophreniaRisperidone 3 mgPaliperidone Palmitate 50 mg eq.Paliperidone Palmitate 75 mg eq.Paliperidone Palmitate 100 mg eq.Paliperidone Palmitate 150 mg eq.Paliperidone Palmitate 175 mg eq.Paliperidone Palmitate 263 mg eq.Paliperidone Palmitate 350 mg eq.
brief summary
The purpose of this study is to assess the long-term symptomatic response (Visit 2 \[Week 1\] to Visit 14/Week 66 \[End of Study {EOS}\]) measured by change in the Clinical Global Impressions -Severity for Schizophrenia (CGI-SS) in participants with schizophrenia who are treated in Rwandan real-world healthcare settings with the antipsychotic regimen that starts with oral anti-psychotic (AP) formulation followed by continued treatment with (paliperidone palmitate 1-month \[PP1M\] and 3-month \[PP3M\] formulations).
started
Jul 22, 2021
primary completion
Apr 16, 2024
completion
Apr 16, 2024
last updated
Apr 27, 2025
official title
Clinical Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol